Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wade Kubat

Plastic Surgery Duluth, MN Doctor of Osteopathy

NPI 1235379256 CMS profile 283123

1012 E 2Nd St, Duluth, MN 55805

Open in the dashboard

General payments

$7,559

71 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wade Kubat of Duluth, MN is reported in the CMS Open Payments database as having received $7,559 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,027 17
2024 General $484 17
2023 General $2,434 15
2021 General $106 4
2020 General $12 1
2019 General $2,496 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wade Kubat
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Wade Kubat were reported at $2,027. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Wade Kubat Plastic Surgery median Middle half National median
2019 $2,496 $371 $122–$1,483 $163
2020 $12 $158 $52–$438 $114
2021 $106 $249 $87–$752 $132
2022 $0 $274 $102–$793 $149
2023 $2,434 $299 $113–$891 $160
2024 $484 $361 $124–$1,062 $164
2025 $2,027 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $2,415 15 payments
  2. AbbVie, Inc. $2,399 15 payments
  3. AxoGen $1,606 7 payments
  4. Mentor Worldwide LLC $630 17 payments
  5. Biocomposites Inc $133 3 payments
  6. Integra LifeSciences Corporation $110 3 payments
  7. RTI Surgical, Inc $74 3 payments
  8. KCI USA, Inc $62 1 payment
  9. Allergan Inc. $25 2 payments
  10. PolyNovo North America LLC $25 1 payment
  11. Other $81 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $5,077 14 payments
  2. Food and Beverage $2,482 57 payments
Products named General payments · program years 2019–2025
  1. PlasmaBlade $2,415 15 payments
  2. NATRELLE SALINE-FILLED BREAST IMPLANTS $2,284 10 payments
  3. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $2,243 9 payments
  4. AXOGUARD Neurology $1,484 5 payments
  5. AXOGUARD Neurology $1,484 5 payments
  6. AXOGUARD HA+ NERVE PROTECTOR $1,484 5 payments
  7. AXOGUARD NERVE CAP $1,484 5 payments
  8. MENTOR MemoryGel Resterilizable Gel Sizer $402 14 payments
  9. ARTOURA Breast Tissue Expander $273 6 payments
  10. Stimulan $133 3 payments
  11. Other $1,025 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

134

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$874

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

51.5%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cefadroxil Generic 40 $237
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 22 $209
Ondansetron Odt Ondansetron Brand 36 $194
Clindamycin Hcl Generic 13 $122
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $85
Tramadol Hcl Generic 12 $27

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$21,824

Medicare's payments for the services billed

Medicare patients

51

Average age 70

Services billed

112

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 67%
Cancer 37%
Chronic kidney disease 25%
Osteoporosis 25%
Depression 24%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record